# Other Cancer Types Aspirin's evidence base extends beyond the main cancer-type pages. Some signals are real but still too limited, mixed, or subtype-specific to justify a full standalone page. This page holds those shorter summaries in one place. ### How to read this page These are **short evidence summaries**, not full cancer pages yet. That usually means one of three things: * the signal is real but still **mixed** * the evidence is only strong in a **narrow subtype** * the biology is interesting, but the **human data is still thin** ### Bladder cancer Bladder cancer needs careful handling because the signal is genuinely mixed. Some post-diagnosis studies suggest a survival benefit with aspirin use after diagnosis, including in people taking aspirin **three or more times per week**. That makes bladder cancer a possible supportive-survival discussion rather than an easy prevention page. But the prevention story is not clean. Some longer-term population cohorts in otherwise healthy people have reported **higher bladder-cancer incidence** in aspirin users. That does **not** prove aspirin causes bladder cancer. It does mean the signal is too conflicted to frame as a straightforward positive page. #### Practical position * **Post-diagnosis use:** Possible supportive survival signal * **Prevention before diagnosis:** Mixed and potentially misleading if oversimplified * **Current status:** Keep here as a balanced caution-and-signal summary ### Lymphoma Lymphoma is not one disease. That matters more than usual here. The aspirin signal appears **subtype-specific**, with the strongest supportive associations reported in **diffuse large B-cell lymphoma**, or **DLBCL**. Some haematologic malignancies show a protective association with aspirin exposure. But the effect is not broad enough across all lymphomas to justify a single positive lymphoma page without more qualification. #### Practical position * **Best-supported area:** **DLBCL** * **Main limit:** Evidence does not generalise cleanly across all lymphoma subtypes * **Current status:** Worth keeping as a short summary, with room for later subtype expansion ### Cervical cancer Cervical cancer has a plausible aspirin biology, but the direct evidence is still limited. The strongest rationale is molecular. **PIK3CA** mutations occur in roughly **20% to 30%** of cervical cancers, which creates a biologically interesting overlap with aspirin-sensitive pathway logic seen more clearly in colorectal cancer. The problem is that the epidemiological evidence is still **limited** and **inconsistent**. That keeps cervical cancer in the “interesting but not established” category. #### Practical position * **Biological rationale:** Real, especially in **PIK3CA-mutant** disease * **Human evidence:** Limited and inconsistent * **Current status:** Appropriate as a brief placeholder summary, not a full page yet ### Not included yet Some cancer types should stay **out of the positive evidence list** for now. #### Leukaemia This should be handled as a **caution**, not a candidate aspirin page. Two major cohorts now report aspirin association with **higher leukaemia risk**. That is exactly the kind of signal that should be noted carefully rather than folded into a positive evidence section. #### Head and neck cancer This also stays out for now. At least one cohort has reported **higher risk with long-term aspirin use**. The wider evidence remains inconsistent, and there is not enough support for a positive summary page. #### Renal cell carcinoma This does not currently justify a page. An older small randomised trial with **176 patients** did **not** show a significant survival benefit, and the modern evidence base remains limited. #### Small bowel cancer There is some signal in **neuroendocrine tumours**, but it is too narrow and too early for a standalone page in this aspirin section. ### Practical interpretation This page is where aspirin signals go when they are: * too mixed for a confident positive page * too narrow to generalise beyond a subtype * biologically interesting, but not ready for full expansion The most important message here is restraint. Not every mechanistic hint deserves a full disease page. And not every observational signal should be read as supportive. ### References General aspirin and cancer reviews\ Repurposing reviews\ Aspirin and metastasis / platelet biology context\

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

{% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/other-cancer-types.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.